Age: 70.0
Sex: F
Vaccine: COVID19
Symptoms: Carbohydrate antigen 125 increased, Disturbance in attention, Investigation, Neoplasm recurrence, Neutrophil count
Clinical narrative: Chemo brain is taking some of the thinking away.; With chemo her weight has fluctuation; but her platelets and neutrophils were low, so they extended it to every four weeks to give her body more time to rebound; but her platelets and neutrophils were low, so they extended it to every four weeks to give her body more time to rebound; her cancer antigen test, called CA125, had started to rise; She is having a recurrence of cancer, which was originally diagnosed in 2020 and was in chemo during her first two shots, so now she is having a recurrence; PET scan showed still had one or two active spots; The initial case was missing the following minimum criteria: No adverse effect. Upon receipt of follow-up information on 08Jun2023, this case now contains all required information to be considered valid.  This is a spontaneous report received from contactable reporter(s) (Consumer or other non-HCP) from medical information team, Program ID: The reporter is the patient.  A 71-year-old female patient received carboplatin (CARBOPLATIN), first regimen since 03Nov2020 and second regimen since 02Mar2023 for fallopian tube cancer, ovarian cancer; paclitaxel (PACLITAXEL), first regimen since 03Nov2020 and second regimen since 02Mar2023 for fallopian tube cancer, ovarian cancer; BNT162b2, BNT162b2 omi ba.4-5 (BNT162B2, BNT162B2 OMI BA.4-5), on 21Oct2022 as dose 5 (booster), single (Lot number: GJ5342) at the age of 70 years for covid-19 immunisation; BNT162b2 (BNT162B2), on 23Jan2021 as dose 1, single (Lot number: EL8982), on 03Mar2021 as dose 2, single (Lot number: EN6202), on 20Aug2021 as dose 3 (booster), single (Lot number: EW0167) and on 20May2022 as dose 4 (booster), single (Lot number: FM9992) for covid-19 immunisation. The patient's relevant medical history was not reported. Concomitant medication(s) included: AVASTIN [ATORVASTATIN CALCIUM]. The following information was reported: POSITRON EMISSION TOMOGRAM ABNORMAL (non-serious) with onset 07Feb2023, outcome "unknown", described as "PET scan showed still had one or two active spots"; DISTURBANCE IN ATTENTION (non-serious), outcome "unknown", described as "Chemo brain is taking some of the thinking away."; WEIGHT FLUCTUATION (non-serious), outcome "unknown", described as "With chemo her weight has fluctuation"; PLATELET COUNT DECREASED (non-serious), NEUTROPHIL COUNT DECREASED (non-serious), outcome "unknown" and all described as "but her platelets and neutrophils were low, so they extended it to every four weeks to give her body more time to rebound"; CARBOHYDRATE ANTIGEN 125 INCREASED (non-serious), outcome "unknown", described as "her cancer antigen test, called CA125, had started to rise"; NEOPLASM RECURRENCE (non-serious), outcome "unknown", described as "She is having a recurrence of cancer, which was originally diagnosed in 2020 and was in chemo during her first two shots, so now she is having a recurrence". Relevant laboratory tests and procedures are available in the appropriate section. The action taken for carboplatin and paclitaxel was unknown.